Managing Chronic Heart Failure in Special Populations

This activity will address the management of heart failure (HF) in older adults, African Americans, patients with diabetes, and patients with poor renal function.
Biykem Bozkurt, MD, PhD, FACC, FAHA, FHFSA
Robert L. Page II, PharmD, MSPH, BCPS (AQ-Cards), BCGP, FCCP, FASHP, FAHA, FHFSA
Released: May 24, 2019

Information on this Educational Activity

Faculty

Biykem Bozkurt, MD, PhD, FACC, FAHA, FHFSA

Professor of Medicine
The Mary and Gordon Cain Chair & W.A. "Tex" and Deborah Moncrief, Jr., Chair
Vice-Chair of Department of Medicine Baylor College of Medicine
Associate Director, Cardiovascular Research Institute
Director, Winters Center for Heart Failure Research
Baylor College of Medicine 
Houston, Texas

Dr. Bozkurt discloses the following: Consultant: Bristol-Myers Squibb, scPharmaceuticals, Inc., Lantheus Medical Imaging, Bayer HealthCare Pharmaceuticals, Respicardia, Abbott Vascular, Anthem, LivaNova
Robert L. Page II, PharmD, MSPH, BCPS (AQ-Cards), BCGP, FCCP, FASHP, FAHA, FHFSA

Professor, Department of Clinical Pharmacy
Clinical Specialist, Division of Cardiology
University of Colorado Anschutz Medical Campus
Aurora, Colorado

Dr. Page has no relevant conflicts of interest to disclose.

Target Audience

Cardiologists, internists, pharmacists, NPs, PAs and other clinicians who encounter patients with HF.

Program Medium

This program has been made available online.

Related Content

From Clinical Care Options (CCO), expert commentary on new data in telehealth for heart failure management from AHA 2021

Lee R. Goldberg, MD, MPH, FACC Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 13, 2021 Expired: December 12, 2022

From Clinical Care Options (CCO), Dr. Lee Goldberg discusses clinical studies of novel therapies for heart failure management presented at AHA 2021

Lee R. Goldberg, MD, MPH, FACC Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 9, 2021 Expired: December 8, 2022

From Clinical Care Options (CCO), expert commentary on new data in heart failure management from AHA 2021

Lee R. Goldberg, MD, MPH, FACC Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 8, 2021 Expired: December 7, 2022

From AHA 2021, new analysis from the CHIEF-HF trial of canagliflozin vs placebo in patients with heart failure, as reported by Clinical Care Options (CCO)

Released: December 3, 2021
Provided by Purdue University
Purdue University Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by an educational grant from
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings